Matinas BioPharma Holdings, Inc.
MTNB
$0.5571
-$0.0429-7.15%
AMEX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | -- |
| Cost of Revenue | 2.24M | 3.37M | 3.45M | 3.67M | 3.30M |
| Gross Profit | -2.24M | -3.37M | -3.45M | -3.67M | -3.30M |
| SG&A Expenses | 2.14M | 2.47M | 2.46M | 2.22M | 2.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.38M | 5.84M | 5.90M | 5.89M | 6.13M |
| Operating Income | -4.38M | -5.84M | -5.90M | -5.89M | -6.13M |
| Income Before Tax | -4.28M | -5.72M | -5.82M | -5.31M | -6.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.28M | -5.72M | -5.82M | -5.31M | -6.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.28M | -5.72M | -5.82M | -5.31M | -6.06M |
| EBIT | -4.38M | -5.84M | -5.90M | -5.89M | -6.13M |
| EBITDA | -4.29M | -5.75M | -5.81M | -5.79M | -6.03M |
| EPS Basic | -0.85 | -1.15 | -1.34 | -1.22 | -1.39 |
| Normalized Basic EPS | -0.53 | -0.72 | -0.84 | -0.76 | -0.87 |
| EPS Diluted | -0.85 | -1.15 | -1.34 | -1.22 | -1.39 |
| Normalized Diluted EPS | -0.53 | -0.72 | -0.84 | -0.76 | -0.87 |
| Average Basic Shares Outstanding | 5.04M | 4.99M | 4.35M | 4.35M | 4.35M |
| Average Diluted Shares Outstanding | 5.04M | 4.99M | 4.35M | 4.35M | 4.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |